What is B. Riley's Forecast for CRBP Q2 Earnings?

Key Points

• B. Riley estimates that Corbus Pharmaceuticals (NASDAQ:CRBP) will report a Q2 2025 earnings loss of ($1.63) per share, maintaining a "Strong-Buy" rating with a target price of $28.00.
• The consensus estimate for Corbus Pharmaceuticals' full-year earnings is anticipated to be ($4.23) per share, with projected losses continuing over the next few fiscal years.
• Corbus Pharmaceuticals' stock has experienced a strong 342% year-to-date surge, but has seen target price reductions from various financial institutions in the past months.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at B. Riley issued their Q2 2025 EPS estimates for Corbus Pharmaceuticals in a research note issued on Wednesday, July 30th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will earn ($1.63) per share for the quarter. B. Riley has a "Strong-Buy" rating and a $28.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals' Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.63) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($5.49) EPS and FY2027 earnings at ($5.50) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.09).

Several other brokerages have also weighed in on CRBP. Lifesci Capital raised Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Saturday, July 12th. Oppenheimer decreased their price target on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada cut their price target on Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright dropped their target price on Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $49.38.

Corbus Pharmaceuticals Stock Down 4.3%

Shares of CRBP traded down $0.40 on Friday, reaching $8.94. The stock had a trading volume of 55,430 shares, compared to its average volume of 192,269. Corbus Pharmaceuticals has a twelve month low of $4.64 and a twelve month high of $61.89. The firm has a 50-day moving average of $8.36 and a 200 day moving average of $7.77. The firm has a market capitalization of $109.38 million, a PE ratio of -2.14 and a beta of 3.20.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP increased its stake in Corbus Pharmaceuticals by 212.3% in the 4th quarter. Two Sigma Investments LP now owns 134,175 shares of the biopharmaceutical company's stock valued at $1,583,000 after buying an additional 91,205 shares during the last quarter. Millennium Management LLC increased its stake in Corbus Pharmaceuticals by 215.0% in the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock valued at $4,563,000 after buying an additional 263,902 shares during the last quarter. Deutsche Bank AG grew its position in shares of Corbus Pharmaceuticals by 46.8% in the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock valued at $97,000 after acquiring an additional 2,616 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Corbus Pharmaceuticals in the 4th quarter valued at about $323,000. Finally, Northern Trust Corp boosted its holdings in shares of Corbus Pharmaceuticals by 12.4% during the 4th quarter. Northern Trust Corp now owns 103,264 shares of the biopharmaceutical company's stock worth $1,219,000 after buying an additional 11,400 shares during the period. 64.64% of the stock is currently owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.